Why is the Orthocell (ASX:OCC) share price falling today?

The Orthocell Ltd (ASX: OCC) share price is sinking this afternoon despite a positive update on its CelGro product.

| More on:
Man thinking and scratching his beard as if asking whether the altium share price is a good buy

Image source: Getty Images

The Orthocell Ltd (ASX: OCC) share price has had a mixed day of trading so far after the company announced a new United States patent for its flagship product.

After tracking as high as 58 cents this morning, shares in the regenerative medicine company have since retreated. At the time of writing, the Orthocell share price is trading down 2.68% to 54.5 cents.

What did Orthocell announce?

In today’s release, Orthocell advised it has been granted a new US divisional patent for CelGro. The patent provides additional intellectual property (IP) to protect the platform for soft tissue regeneration and repair applications, and expires in June 2033.

Orthocell also revealed it had secured 11 patent families that protect its intellectual property. This includes 110 separate patents/applications, of which 75 have already been granted.

Manufactured in Western Australia, the company believes CelGro has numerous competitive advantages over existing synthetic and biologic tissue repair products. Orthocell said CelGro was known to be superior in cell biocompatibility, tensile strength and tissue repair. The medical device has shown positive results in repairing bone defects in the jaw, assisted in re-joining severed or damaged peripheral nerves, and enhanced restoration of the rotator cuff tendon (shoulder).

Branded as Striate+ in the United States, the CelGro Dental platform will be used for dental bone and tissue regenerations procedures. This includes dental bone repairs, growth around dental implants in extraction sockets, and tissue regeneration in intrabony defects.

Management commentary

Orthocell managing director Paul Anderson welcomed the recent patent approval, saying:

This is an important patent that further protects and strengthens our IP position for CelGro, providing greater layers of protection. This patent also complements the recent market approval of the first CelGro product, Striate+ for dental bone and soft tissue repair procedures approved in the US, EU and Australia.

Orthocell share price snapshot

The Orthocell share price is up almost 20% over the last 12 months. The company’s shares hit a low of 18 cents in last year’s COVID-19 market rout in March, before quickly rebounding. 

Based on the current share price, Orthocell has a market capitalisation of around $104 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News